<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00805519</url>
  </required_header>
  <id_info>
    <org_study_id>870919</org_study_id>
    <nct_id>NCT00805519</nct_id>
  </id_info>
  <brief_title>Efficacy and Safety of Prednisolone and Chloroquine Add on Therapy in Osteoarthritis of the Knee</brief_title>
  <official_title>Efficacy and Safety of Prednisolone and Chloroquine Add on Therapy in Osteoarthritis of the Knee Treated With Fixed Dose Combination of Glucosamine and Chondroitin Sulfate.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Ardabil University of Medical Sciences</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Ardabil University of Medical Sciences</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study was conducted to evaluate the efficacy and safety of prednisolone and chloroquine
      add on therapies to combined glucosamine, chondroitin sulfate in osteoarthritis of the knee
      which will be done in contrast to combined glucosamine sulfate and chondroitin.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Fixed dose glucosamine, chondroitin sulfate combination is a treatment to osteoarthritis with
      some controversy about efficacy. it seems that addition of other agents may improve efficacy
      and decrease the required dose and cost. common oral corticosteroids such as low dose
      prednisolone and chloroquine are candidate for such add on therapies. nevertheless, add on
      therapy may expose the patients to new side effects which should followed and addressed.

      In this investigator blinded controlled trial, 240 patients with diagnosed osteoarthritis of
      knee will be enrolled to the study. the patients will randomly be assigned to one of four
      groups of G (glucosamine and chondroitin sulfate ), P (Glucosamine and Chondroitin sulfate
      plus Prednisolone), C (Glucosamine and Chondroitin sulfate plus Chloroquine) and PC
      (Glucosamine and Chondroitin sulfate plus Prednisolone and Chloroquine). each group will
      consist 60 patients. the investigator(s) will be blind to the groups and interventions.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>February 2009</start_date>
  <completion_date type="Actual">April 2010</completion_date>
  <primary_completion_date type="Actual">April 2010</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Single (Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>The primary outcome measures is defined as the change from baseline to final assessment of the study knee in the 3 core continuous variables pain and physical function, assessing using the WOMAC subscales, and patient global assessment (PGA)</measure>
    <time_frame>Baseline</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>The primary outcome measures is defined as the change from baseline to final assessment of the study knee in the 3 core continuous variables pain and physical function, assessing using the WOMAC subscales, and patient global assessment (PGA)</measure>
    <time_frame>the outcome is assessed at 6 weeks after baseline visit</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>The primary outcome measures is defined as the change from baseline to final assessment of the study knee in the 3 core continuous variables pain and physical function, assessing using the WOMAC subscales, and patient global assessment (PGA)</measure>
    <time_frame>the outcome is assessed at 12 weeks after baseline visit</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>The secondary measure will be changes in stiffness</measure>
    <time_frame>the outcome is assessed at baseline visit</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The secondary measure will be changes in stiffness</measure>
    <time_frame>the outcome is assessed at 6 weeks after baseline visit</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The secondary measure will be changes in stiffness</measure>
    <time_frame>the outcome is assessed at 12 weeks after baseline visit</time_frame>
  </secondary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Actual">230</enrollment>
  <condition>Osteoarthritis of the Knee</condition>
  <arm_group>
    <arm_group_label>Glucosamine and chondroitin sulfate</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>in this group patients will receive Glucosamine and chondroitin sulfate oral dietary supplementation</description>
  </arm_group>
  <arm_group>
    <arm_group_label>P :glucosa, chondroitin, Prednis</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>in this group patients will receive glucosamine and chondroitin sulfate plus Prednisolone oral administration</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Glucosa, Chondroitin, Chloroquine</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>in this group pateints will orally receive Glucosamine and Chondroitin sulfate plus Chloroquine.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Glucosa, Chondro, Prednis,Chloroq</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>in this group patients will receive Glucosamine and Chondroitin sulfate plus Prednisolone and Chloroquine</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Glucosamine and chondroitin sulfate</intervention_name>
    <description>In this arm fixed dose glucosamine (400 mg) and chondroitin sulfate (500 mg)combination will be administrated to the patients, daily.</description>
    <arm_group_label>Glucosamine and chondroitin sulfate</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>glucosamine and chondroitin sulfate plus Prednisolone</intervention_name>
    <description>In this arm fixed dose glucosamine (400 mg) and chondroitin sulfate (500 mg)combination will be administrated to the patients as baseline therapy, daily. also,the patients will receive Prednisolone 5 mg/day</description>
    <arm_group_label>P :glucosa, chondroitin, Prednis</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Glucosamine and Chondroitin sulfate plus Chloroquine</intervention_name>
    <description>In this arm fixed dose glucosamine (400 mg) and chondroitin sulfate (500 mg)combination will be administrated to the patients as baseline therapy, daily. also,the patients will receive chloroquine 150 mg every two days.</description>
    <arm_group_label>Glucosa, Chondroitin, Chloroquine</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Glucosamine,Chondroitin sulfate,Prednisolone,Chloroquine</intervention_name>
    <description>In this arm fixed dose glucosamine (400 mg) and chondroitin sulfate (500 mg)combination will be administrated to the patients as baseline therapy, daily. also,the patients will receive prednisolone 5 mg/day and chloroquine 150 mg every two days.</description>
    <arm_group_label>Glucosa, Chondro, Prednis,Chloroq</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  men and non-pregnant women, age 40-85 years with primary OA of at least one knee.

        Exclusion Criteria:

          -  secondary arthritis related to systemic inflammatory arthritis (including rheumatoid
             arthritis, psoriatic arthritis, post-infectious arthritis and metabolic arthritis,
             traumatic arthritis or surgical joint replacement)corticosteroid use:

               -  oral corticosteroid within the previous 14 days

               -  intramuscular corticosteroid within 30 days

               -  intraarticular corticosteroid into the study knee within 90 days

               -  intra-articular corticosteroid into any other joint within 30 days or

               -  topical corticosteroid at the site of application within 14 days

          -  ongoing use of prohibited medication including NSAID, other oral analgesic, muscle
             relaxant, or low-dose antidepressant for any chronic pain management

          -  glucosamine or chondroitin within the previous six months

          -  history of alcohol or drug abuse

          -  lactation

          -  concomitant skin disease at the application site

          -  current application for disability benefits on the basis of knee osteoarthritis;
             fibromyalgia; other painful or disabling condition affecting the knee
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>40 Years</minimum_age>
    <maximum_age>85 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Shahab Bohlooli, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Pharmacology Dept, Faculty of Medicine, ArdabilUMS</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Marina Jastan, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Rheomatology clinic, Faculty of Medicine, ArdabilUMS</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>ArdabiUMS Clinic of Rheumatology</name>
      <address>
        <city>Ardabil</city>
        <zip>56197</zip>
        <country>Iran, Islamic Republic of</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Iran, Islamic Republic of</country>
  </location_countries>
  <verification_date>April 2010</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>December 8, 2008</study_first_submitted>
  <study_first_submitted_qc>December 8, 2008</study_first_submitted_qc>
  <study_first_posted type="Estimate">December 9, 2008</study_first_posted>
  <last_update_submitted>April 29, 2010</last_update_submitted>
  <last_update_submitted_qc>April 29, 2010</last_update_submitted_qc>
  <last_update_posted type="Estimate">April 30, 2010</last_update_posted>
  <responsible_party>
    <name_title>Shahab Bohlooli</name_title>
    <organization>Pharmacology Dept., Faculty of Medicine, ArdabilUMS</organization>
  </responsible_party>
  <keyword>Osteoarthritis of the Knee</keyword>
  <keyword>Glucosamine Chondroitin sulfate</keyword>
  <keyword>Prednisolone</keyword>
  <keyword>Chloroquine</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Osteoarthritis</mesh_term>
    <mesh_term>Osteoarthritis, Knee</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Prednisolone acetate</mesh_term>
    <mesh_term>Methylprednisolone acetate</mesh_term>
    <mesh_term>Chloroquine diphosphate</mesh_term>
    <mesh_term>Prednisolone</mesh_term>
    <mesh_term>Methylprednisolone</mesh_term>
    <mesh_term>Methylprednisolone Hemisuccinate</mesh_term>
    <mesh_term>Prednisolone hemisuccinate</mesh_term>
    <mesh_term>Prednisolone phosphate</mesh_term>
    <mesh_term>Chloroquine</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

